LARGUE PHARMACY LIMITED

Company Registration Number:
SC257732 (Scotland)

Unaudited abridged accounts for the year ended 31 August 2025

Period of accounts

Start date: 01 September 2024

End date: 31 August 2025

LARGUE PHARMACY LIMITED

Contents of the Financial Statements

for the Period Ended 31 August 2025

Balance sheet
Notes

LARGUE PHARMACY LIMITED

Balance sheet

As at 31 August 2025


Notes
2025
2024


£
£
Called up share capital not paid: 0 0
Fixed assets
Intangible assets: 3 205,000 246,000
Tangible assets: 4 224,550 251,422
Investments:   0 0
Total fixed assets: 429,550 497,422
Current assets
Stocks: 192,418 184,252
Debtors:   233,656 231,245
Cash at bank and in hand: 636,213 578,328
Total current assets: 1,062,287 993,825
Creditors: amounts falling due within one year:   (386,905) (396,074)
Net current assets (liabilities): 675,382 597,751
Total assets less current liabilities: 1,104,932 1,095,173
Creditors: amounts falling due after more than one year:   (38,685) (29,214)
Provision for liabilities: (48,040) (58,942)
Total net assets (liabilities): 1,018,207 1,007,017
Capital and reserves
Called up share capital: 1,250 1,250
Share premium account: 0 0
Revaluation reserve: 00
Other reserves: 0 0
Profit and loss account: 1,016,957 1,005,767
Shareholders funds: 1,018,207 1,007,017

The notes form part of these financial statements

LARGUE PHARMACY LIMITED

Balance sheet statements

For the year ending 31 August 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 12 December 2025
and signed on behalf of the board by:

Name: Gordon A Largue
Status: Director

The notes form part of these financial statements

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2025

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2025

2. Employees

2025 2024
Average number of employees during the period 22 22

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2025

3. Intangible Assets

Total
Cost £
At 01 September 2024 1,250,000
Additions 0
Disposals 0
Revaluations 0
Transfers 0
At 31 August 2025 1,250,000
Amortisation
At 01 September 2024 1,004,000
Charge for year 41,000
On disposals 0
Other adjustments 0
At 31 August 2025 1,045,000
Net book value
At 31 August 2025 205,000
At 31 August 2024 246,000

LARGUE PHARMACY LIMITED

Notes to the Financial Statements

for the Period Ended 31 August 2025

4. Tangible Assets

Total
Cost £
At 01 September 2024 612,978
Additions 0
Disposals 0
Revaluations 0
Transfers 0
At 31 August 2025 612,978
Depreciation
At 01 September 2024 361,556
Charge for year 26,872
On disposals 0
Other adjustments 0
At 31 August 2025 388,428
Net book value
At 31 August 2025 224,550
At 31 August 2024 251,422